Latest Multiple Sclerosis Treatments: 5 Options Today
Multiple Sclerosis treatment is evolving fast, giving people more choices than ever.
In this guide, we break down five of the latest MS therapies, what benefits they offer, how effective they are, how they compare with older drugs, and practical steps to access them.How we chose these 5 “latest” options
We focused on therapies approved in recent years or now widely adopted in practice, backed by large clinical trials and real-world data, and available (or accessible via referral) in many countries. For broad background on disease-modifying therapies (DMTs), see the National MS Societys overview of MS medications (NMSS DMTs).
Every persons MS is different. Effectiveness and risks vary by MS subtype, age, relapse history, MRI activity, comorbidities, and pregnancy plans. Decisions should be individualized with your MS neurologist and follow evidence-based guidance (see American Academy of Neurology DMT guidance summaries: AAN guidelines).
1) Ofatumumab (Kesimpta): self-injected anti-CD20 B-cell therapy
Benefits
- High-efficacy therapy delivered as a once-monthly at-home injection after initial loading.
- Targets CD20+ B cells, a key driver of inflammatory MS activity.
- No infusion chair time; convenient for people far from infusion centers.
Effectiveness
In the ASCLEPIOS I/II trials, ofatumumab significantly lowered annualized relapse rates and new MRI lesions versus teriflunomide, and reduced risk of confirmed disability worsening. See trial summary (ASCLEPIOS).
How it compares
Similar efficacy class to infused anti-CD20 drugs (e.g., ocrelizumab, ublituximab). Compared with older platform therapies (interferons, glatiramer acetate), it generally achieves larger relapse and MRI lesion reductions. Compared with infusions, at-home dosing can be more convenient, though monitoring for infections and vaccination timing remain essential.
How to access
Discuss with your neurologist; insurers often require documentation of relapses or MRI activity. Baseline labs and screening (e.g., hepatitis B, immunizations) are typical. Medication is dispensed via specialty pharmacy with nurse support for first doses. The NMSS outlines insurance and financial resources (NMSS insurance help).
2) Ublituximab (Briumvi): faster-infusion anti-CD20
Benefits
- High-efficacy B-cell therapy with a streamlined infusion schedule after loading.
- Shorter infusion times (often about 1 hour for maintenance), reducing clinic time.
Effectiveness
The ULTIMATE I/II trials showed significantly lower relapse rates and MRI lesion counts versus teriflunomide, with favorable disability outcomes; see the study publication (ULTIMATE trials).
How it compares
Comparable overall efficacy to other anti-CD20 options. Shorter infusion times can be a practical advantage over some alternatives. Safety profile is similar to the class: infusion reactions, infection risk (including hypogammaglobulinemia over time), and vaccination planning considerations.
How to access
Initiation typically occurs at an infusion center. Your care team will arrange pre-infusion labs, vaccinations, and premedication. Many insurers cover anti-CD20 therapies for relapsing forms of MS with prior authorization; your clinics infusion coordinator can help navigate benefits.
3) Next-gen S1P modulators: ozanimod (Zeposia) and ponesimod (Ponvory)
Benefits
- Oral once-daily dosing after initial titration.
- Fewer first-dose cardiac monitoring requirements than older S1Ps for many patients.
- Robust MRI lesion control with convenient oral administration.
Effectiveness
Ozanimod reduced relapses and MRI activity versus interferon beta-1a in large trials (SUNBEAM/RADIANCE). Ponesimod outperformed teriflunomide for relapse reduction and MRI outcomes and showed advantages on fatigue measures in one study (OPTIMUM).
How it compares
These newer S1Ps generally offer improved convenience over first-generation fingolimod with similar or better efficacy versus older platform therapies. Compared with anti-CD20s, population-level relapse reductions may be somewhat smaller, but S1Ps avoid infusion logistics and may better suit some patients preferences and risk profiles.
How to access
Cardiac history review, baseline ECG (as indicated), and ophthalmic and liver tests are common. Insurers often cover these agents for relapsing MS; specialty pharmacies manage dispensing. Your clinician will advise on contraception, infection screening, and vaccine timing.
4) Cladribine (Mavenclad): short-course immune reconstitution therapy
Benefits
- Oral tablets given in two annual courses (a few dosing days each year), with durable effects for many patients.
- Convenient between-course periods off continuous therapy.
Effectiveness
In the CLARITY trial, cladribine significantly reduced relapses and MRI lesion activity versus placebo and showed reductions in confirmed disability progression (CLARITY).
How it compares
Effectiveness is generally higher than older platform therapies and competitive with other high-efficacy options for relapsing MS. It requires careful lymphocyte monitoring and infection risk management, and it is contraindicated in pregnancy during and for a period after treatment.
How to access
Access is via MS specialists familiar with immune reconstitution therapy. Expect baseline labs (including lymphocyte counts, hepatitis screening, and VZV immunity), cancer screening per guidelines, and pregnancy testing/contraception counseling where relevant. Payer criteria and safety monitoring plans are typically required.
5) Autologous hematopoietic stem cell transplantation (AHSCT)
Benefits
- For highly active relapsing MS, AHSCT can induce deep disease quiescence (no evidence of disease activity) in many patients.
- Single upfront procedure with potential long-term control without ongoing DMTs.
Effectiveness
Randomized and cohort studies (e.g., the MIST trial) showed substantial reductions in relapses and disability worsening versus conventional DMT escalation in aggressive relapsing MS (MIST). Professional societies have updated recommendations to define candidates and center standards (EBMT guidance).
How it compares
Among the most potent options for inflammatory relapsing MS, but with higher short-term risks (myeloablation, infection, hospitalization) and the need for experienced centers. Not typically used for progressive MS without inflammatory activity.
How to access
Referral to an AHSCT-experienced MS center is essential. Insurer coverage varies; many require documentation of highly active disease after high-efficacy DMTs. The National MS Society maintains resources on HSCT and where its offered (NMSS on HSCT).
Quick comparison at a glance
- Highest efficacy (inflammation control): Anti-CD20s (ofatumumab/ublituximab), AHSCT.
- Oral convenience with solid efficacy: Ozanimod, ponesimod, cladribine (short-course).
- Clinic time: Ofatumumab (home injection) minimizes visits; ublituximab offers short infusions; AHSCT requires hospitalization but is time-limited.
- Monitoring needs: All require labs and infection screening; S1Ps add cardiac/eye checks; cladribine requires lymphocyte monitoring and pregnancy planning.
Whats on the horizon?
Brutons tyrosine kinase (BTK) inhibitors are in late-stage trials and aim to target both B cells and myeloid cells within the CNS. Some agents have shown promising MRI and relapse outcomes, but none are widely approved for MS at the time of writing; ask about trials if youre interested (ClinicalTrials.gov). For an overview of BTK inhibitors in MS, see this review (BTKi review).
How to access these treatments: a practical checklist
1) Book a comprehensive MS review
Schedule a visit with your MS specialist to review relapses, MRI trends, disability scores, infection history, vaccinations, pregnancy plans, and lifestyle goals. Bring your latest MRI and lab results.
2) Match the therapy to your goals and risk profile
Discuss trade-offs between efficacy, safety, monitoring, convenience, and family planning. High-efficacy early strategies may prevent disability for people with active disease; others may prioritize lower monitoring burdens.
3) Prep for coverage and logistics
- Have your clinic submit prior authorization with clinical notes and MRI evidence.
- Ask about foundation support and manufacturer programs; NMSS lists resources (financial support).
- Plan vaccinations before B-cell therapies or AHSCT when possible.
4) Set up monitoring
Clarify the lab schedule (CBC, liver enzymes, immunoglobulins), infection screening, and imaging cadence. Know who to contact for new symptoms and how to handle missed doses or infusion delays.
5) Reassess regularly
Review treatment response at least annually: relapses, MRI activity, disability measures, tolerability, and life changes. Be ready to switch if disease activity breaks through.
Key takeaway
Todays Multiple Sclerosis treatments offer more power and flexibility than everfrom self-injected and oral options to hospital-based AHSCT. Work with your neurologist to align the right therapy to your disease activity and life goals, and use the steps above to access care efficiently.